We are live on ! Find out more
CRL icon

Charles River Laboratories

676 hedge funds and large institutions have $19.3B invested in Charles River Laboratories in 2021 Q3 according to their latest regulatory filings, with 83 funds opening new positions, 238 increasing their positions, 256 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

124% more first-time investments, than exits

New positions opened: 83 | Existing positions closed: 37

33% more call options, than puts

Call options by funds: $128M | Put options by funds: $96.7M

25% more funds holding in top 10

Funds holding in top 10: 1620 (+4)

10% more capital invested

Capital invested by funds: $17.6B → $19.3B (+$1.74B)

6% more funds holding

Funds holding: 638676 (+38)

7% less repeat investments, than reductions

Existing positions increased: 238 | Existing positions reduced: 256

1.75% less ownership

Funds ownership: 94.66%92.91% (-1.7%)

Holders
676
Holders Change
+38
Holders Change %
+5.96%
% of All Funds
11.83%
Holding in Top 10
20
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+25%
% of All Funds
0.35%
New
83
Increased
238
Reduced
256
Closed
37
Calls
$128M
Puts
$96.7M
Net Calls
+$31.6M
Net Calls Change
+$32.8M
Name Holding Trade Value Shares
Change
Change in
Stake
DILIC
151
Dai-ichi Life Insurance Company
Japan
$11.6M
Lazard Asset Management
152
Lazard Asset Management
New York
$11.3M -$41.8M -100,626 -79%
Toronto Dominion Bank
153
Toronto Dominion Bank
Ontario, Canada
$11.3M +$2.24M +5,386 +24%
OAM
154
Oppenheimer Asset Management
New York
$10.8M -$871K -2,098 -7%
CCM
155
Channing Capital Management
Illinois
$10.8M -$3.52M -8,486 -24%
Connor, Clark & Lunn Investment Management (CC&L)
156
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$10.6M +$7.66M +18,446 +251%
PHP
157
Parkman Healthcare Partners
Connecticut
$10.3M -$11.3M -27,245 -52%
Asset Management One
158
Asset Management One
Japan
$10.3M +$396K +953 +4%
Assenagon Asset Management
159
Assenagon Asset Management
Luxembourg
$10.1M -$8.17M -19,669 -44%
Natixis Advisors
160
Natixis Advisors
Massachusetts
$9.87M -$939K -2,262 -9%
US Bancorp
161
US Bancorp
Minnesota
$9.85M -$39K -94 -0.4%
Aviva
162
Aviva
United Kingdom
$9.82M +$6.05M +14,577 +158%
GGHC
163
Gilder Gagnon Howe & Co
New York
$9.45M -$2.08K -5 -0%
Two Sigma Advisers
164
Two Sigma Advisers
New York
$9.45M +$9.51M +22,900 New
Canada Life
165
Canada Life
Manitoba, Canada
$9.44M +$3.65M +8,798 +63%
SAM
166
Sectoral Asset Management
Quebec, Canada
$9.41M
Mitsubishi UFJ Asset Management
167
Mitsubishi UFJ Asset Management
Japan
$9.33M +$879K +2,116 +10%
FFA
168
Fragasso Financial Advisors
Pennsylvania
$9.3M -$79.7K -192 -0.8%
VAS
169
Vestmark Advisory Solutions
Massachusetts
$9.13M +$910K +2,190 +11%
Susquehanna International Group
170
Susquehanna International Group
Pennsylvania
$9.08M -$39.9K -96 -0.4%
AAM
171
Advisors Asset Management
Colorado
$9.06M +$991K +2,385 +12%
GC
172
Guggenheim Capital
Illinois
$8.98M +$672K +1,619 +8%
FAF
173
Första AP-fonden
Sweden
$8.83M +$2.62M +6,300 +42%
LCM
174
Logan Capital Management
Pennsylvania
$8.59M -$254K -611 -3%
Robeco Institutional Asset Management
175
Robeco Institutional Asset Management
Netherlands
$8.51M +$2.54M +6,125 +42%

CRL Hedge Fund Activity: Q3 2021 in Review

676 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q3 2021, worth a combined $19.3B — up 9.9% from $17.6B a quarter earlier.

Buyers outnumbered sellers: 83 funds opened new CRL positions and 37 closed out — a net gain of 46 holders — while 238 added to existing stakes and 256 trimmed.

The largest buyer was Melvin Capital Management, opening a new position worth an estimated $156M. The largest seller was Ameriprise, cutting an estimated $242M.

  • 676 institutional investors held Charles River Laboratories (CRL) as of Q3 2021, up from 638 in Q2 2021.
  • Funds reported $19.3B of Charles River Laboratories stock for Q3 2021, up 9.9% quarter-over-quarter.
  • 83 funds opened new Charles River Laboratories positions in Q3 2021 and 37 closed out, a net change of +46 holders.
  • The largest Charles River Laboratories buyer in Q3 2021 was Melvin Capital Management, an estimated $156M added.
  • The largest Charles River Laboratories seller in Q3 2021 was Ameriprise, an estimated $242M sold.

Based on aggregated 13F filings for Q3 2021.